Coya Therapeutics (NASDAQ:COYA) Downgraded by Wall Street Zen to Sell

Coya Therapeutics (NASDAQ:COYA) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Other research analysts have also issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, January 21st. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, February 2nd. Chardan Capital reaffirmed a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Monday, March 16th. Finally, D. Boral Capital reiterated a “buy” rating and set a $15.00 price objective on shares of Coya Therapeutics in a report on Monday, March 16th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Coya Therapeutics Trading Down 1.4%

Shares of COYA stock opened at $4.21 on Friday. The company has a market capitalization of $98.77 million, a price-to-earnings ratio of -3.31 and a beta of 0.23. Coya Therapeutics has a 1-year low of $3.94 and a 1-year high of $7.75. The stock’s fifty day simple moving average is $4.69 and its 200-day simple moving average is $5.53.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings data on Monday, March 16th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.26). The business had revenue of $3.96 million for the quarter, compared to analyst estimates of $1.93 million. Coya Therapeutics had a negative return on equity of 62.76% and a negative net margin of 267.13%. On average, sell-side analysts predict that Coya Therapeutics will post -1.15 EPS for the current year.

Hedge Funds Weigh In On Coya Therapeutics

Hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. acquired a new position in Coya Therapeutics during the third quarter worth $28,000. CIBC Private Wealth Group LLC acquired a new stake in shares of Coya Therapeutics in the fourth quarter worth about $47,000. Occudo Quantitative Strategies LP acquired a new stake in shares of Coya Therapeutics in the fourth quarter worth about $66,000. Lantern Wealth Advisors LLC bought a new stake in shares of Coya Therapeutics during the 3rd quarter worth about $66,000. Finally, Oppenheimer & Co. Inc. acquired a new position in shares of Coya Therapeutics during the 4th quarter valued at about $81,000. 39.75% of the stock is owned by institutional investors and hedge funds.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.